NIKKEI 225
26,153.81 +218.19 (+0.84%) HANG SENG
21,830.35 -29.44 (-0.13%) CRUDE OIL
110.30 +1.87 (+1.72%) GOLD FUTURES
1,807.40 +5.90 (+0.33%) DOW
31,097.26 +321.86 (+1.05%) BTC-GBP
16,394.82 -230.93 (-1.39%)
Onxeo SA (0NWK.L)
| Previous close | 0.7305 |
| Open | 0.3720 |
| Bid | 0.0000 x 0 |
| Ask | 0.0000 x 0 |
| Day's range | 0.3720 - 0.3720 |
| 52-week range | 0.3720 - 0.3720 |
| Volume | |
| Avg. volume | N/A |
| Market cap | 21.02M |
| Beta (5Y monthly) | 1.46 |
| PE ratio (TTM) | N/A |
| EPS (TTM) | -0.1230 |
| Earnings date | N/A |
| Forward dividend & yield | N/A (N/A) |
| Ex-dividend date | N/A |
| 1y target est | N/A |
- Business Wire
Summary of ONXEO’s Liquidity Contract with Kepler Cheuvreux
PARIS, July 04, 2022--Regulatory News: Under the liquidity contract entered into between ONXEO (Paris:ALONX) (NASDAQ OMX:ONXEO) and Kepler Cheuvreux, the following resources appeared on the liquidity account on June 30th 2021:
- Business Wire
Onxeo: Initial IND Application for AsiDNA Granted "Study May Proceed" by the U.S. FDA
PARIS, June 30, 2022--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), hereafter "Onxeo" or the "Company", a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), today announced that the U.S. Food and Drug Administration (FDA) has cleared the initial IND for its first-in-class drug candidate AsiDNA. This is the first US IND Onxeo filed since the US team came on board in
- Business Wire
Onxeo: Proceedings of the Combined Shareholders’ Meeting of June 15, 2022
PARIS, June 16, 2022--Regulatory News: Onxeo S.A. (Euronext Growth Paris: ALONX, Nasdaq First North Copenhagen: ONXEO), ("Onxeo" or the "Company"), a clinical-stage biotechnology company specializing in the development of innovative drugs targeting tumor DNA Damage Response (DDR), in particular against rare or resistant cancers, announces that the Combined General Meeting held today adopted all resolutions presented, in accordance with the Board of Directors’ recommendations.
